NEW YORK (GenomeWeb News) – DxTerity Diagnostics and Caliper Life Sciences today announced a deal that will allow researchers to perform DxTerity's NEAT multiplex diagnostic assays on Caliper's LabChip Dx instrument platform.
The co-development and co-marketing deal also includes the development by the firms of specific diagnostic identification, scoring, and reporting software.
Financial and other terms were not disclosed.
DxTerity's NEAT assays are for the analysis and detection of SNPs directly from blood or formalin-fixed paraffin-embedded tissue. The company's lead clinical product being developed is a blood screening test for measuring a patient's exposure to radiation following a nuclear event, such as the recent event in Fukushima, Japan, it said, adding the product is planned to launch in June 2012.
DxTerity also said that it is developing low-cost, blood-based cancer screening tests based on gene signature panels acquired from SourceMDx.
"DxTerity's simple and robust NEAT assays, combined with the ease-of-use of the Caliper LabChip Dx system will eliminate significant barriers to the use of multiplex genomic tests in the clinical laboratory and lead to major gains in personalized medicine," DxTerity President and CEO Bob Terbrueggen, said in a statement.
Caliper's LabChip Dx enables high-throughput multiplex analysis for the discovery and analysis of nucleic acid and protein biomarkers.
"We believe this collaboration with DxTerity will result in a significant expansion of the number and type of tests available for readout by the LabChip Dx platform," Caliper CEO Kevin Hrusovsky said. DxTerity's assays "align with Caliper's vision for the future of medicine where molecular diagnostics are increasingly used to characterize disease and select the proper course of treatment," he added.
Caliper is in the process of being acquired by PerkinElmer for $600 million.